Alvogen Appoints Graham Baker as Chief Financial Officer

- Kevin Bain becomes EVP of Strategic Development and CFO of Alvotech

PINE BROOK, N.J.--(BUSINESS WIRE)--Alvogen, today announced that Kevin Bain, the Company's Chief Financial Officer since 2009 will take on the role of Chief Financial Officer of Alvogen's biotech sister company, Alvotech and continue as EVP of Strategic Development at Alvogen.

"I am delighted to be joining a world class business like Alvogen, which has a very impressive growth story. I look forward to working closely with Alvogen's employees and shareholders.""
Alvogen is also delighted to announce that Graham Baker will be appointed as the group's new Chief Financial Officer, effective 1 November 2015. Graham joins Alvogen from AstraZeneca, where he has spent the past 20 years of his career, most recently as Vice President of Finance for AstraZeneca's international business. Graham will be responsible for all global finance and information services for Alvogen.

"Kevin has played a pivotal role at Alvogen over the past six years. He has provided crucial support for our business as we have transformed from a small U.S. contract manufacturer to a global generic pharmaceutical company with commercial operations in 35 countries," said Robert Wessman, Chairman and CEO of Alvogen. "We are very appreciative of his contributions to the company and are excited to have him take on the challenges of this new role."

Commenting on Graham Baker's appointment, Robert Wessman continued: "We are pleased to welcome Graham Baker to the executive team during this exciting time as we continue to deliver tremendous growth. Graham brings a wealth of global experience that will be invaluable to our organization as we work towards our ambition to become a leading global player in the generics market. Graham has built a strong reputation for leading the transformation of large global companies; this experience will help us to take advantage of the many opportunities presented by the critical change the pharmaceutical industry is currently undergoing. We look forward working with Graham as we further expand our business around the world and create value for our customers and the patients we serve."

Graham Baker added: "I am delighted to be joining a world class business like Alvogen, which has a very impressive growth story. I look forward to working closely with Alvogen's employees and shareholders."

Graham, 47, has over 24 years of finance experience and qualified as a Chartered Accountant and Chartered Tax Advisor working for Arthur Andersen. Graham holds an MA degree in Economics from Cambridge University in England.

About Alvogen

Alvogen is a global, privately owned pharmaceutical company focused on developing, manufacturing and selling generic, brand, over-the-counter brands (OTC) and biosimilar products for patients around the world.

The company has commercial operations in 35 countries with 2,300 employees and operates four manufacturing and development hubs in the US, Romania, Korea and Taiwan. North America is Alvogen's single largest market and other key markets include: South Korea, West Balkan, Poland, Romania, Bulgaria, Hungary, Taiwan, Thailand, Ukraine, Russia, Japan and China.


Halldor Kristmannsson
Global Corporate Marketing & Communications
(+354) 522 2900
[email protected]

Suggested Articles

Adimab spinout Adagio Therapeutics raised $50 million to develop antibodies that target SARS-CoV-2 and other coronaviruses.

Relay Therapeutics has pulled off a major upsized IPO worth $400 million to propel a pipeline of treatments aiming at previously undruggable targets.

The series C follows phase 1b data on the brain cancer treatment that persuaded existing investors including HP WILD to commit more cash.